Cargando…
Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study,...
Autores principales: | Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Albogami, Sarah M., Jean-Marc, Sabatier, Nadwa, Eman Hassan, Hafiz, Amin A., A. Negm, Walaa, Kamal, Marwa, Al-Jouboury, Mohammed, Elekhnawy, Engy, Batiha, Gaber El-Saber, Waard, Michel De |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699540/ https://www.ncbi.nlm.nih.gov/pubmed/36355535 http://dx.doi.org/10.3390/ph15111361 |
Ejemplares similares
-
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best
por: Nadwa, Eman Hassan, et al.
Publicado: (2022) -
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
por: Alomair, Basil Mohammed, et al.
Publicado: (2022) -
Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail
por: Al-kuraishy, Hayder M., et al.
Publicado: (2022) -
Nitazoxanide and COVID-19: A review
por: Al-kuraishy, Hayder M., et al.
Publicado: (2022) -
Potential role of lipoxin in the management of COVID-19: a narrative review
por: Batiha, Gaber El-Saber, et al.
Publicado: (2022)